INNATE PHARMA SA-SPONS ADR (IPHA)
US45781K2042 - ADR
In today's session, these stocks are experiencing unusual volume.
The trading volume of these stocks is deviating from the norm in today's session.
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
Stay updated with the stocks that are on the move in today's after-hours session.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Which stocks are moving on Friday?
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
These stocks have an unusual volume in today's session
These stocks have an unusual volume in today's session
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Unusual volume stocks in Tuesday's session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
Innate Pharma Releases Its 2025 Financial Calendar
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
Innate Pharma Reports First Half 2024 Business Update and Financial Results
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning!
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
Outcome of Innate Pharma’s 2024 Annual General Meeting
Innate Pharma: Clarification Regarding SAR443579 Designation
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
